> top > docs > PubMed:11240980 > annotations

PubMed:11240980 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 35-42 gene:1557 denotes CYP2C19
T1 61-90 disease:C0850666 denotes Helicobacter pylori infection
T2 116-127 gene:495 denotes proton pump
T3 61-90 disease:C0850666 denotes Helicobacter pylori infection
T4 116-127 gene:479 denotes proton pump
T5 61-90 disease:C0850666 denotes Helicobacter pylori infection
R1 T0 T1 associated_with CYP2C19,Helicobacter pylori infection
R2 T2 T3 associated_with proton pump,Helicobacter pylori infection
R3 T4 T5 associated_with proton pump,Helicobacter pylori infection

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
11240980-0#35#42#gene1557 35-42 gene1557 denotes CYP2C19
11240980-0#61#90#diseaseC0850666 61-90 diseaseC0850666 denotes Helicobacter pylori infection
35#42#gene155761#90#diseaseC0850666 11240980-0#35#42#gene1557 11240980-0#61#90#diseaseC0850666 associated_with CYP2C19,Helicobacter pylori infection

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 184-390 BACKGROUND denotes Proton pump inhibitors such as omeprazole and lansoprazole are mainly metabolized by CYP2C19 in the liver. The therapeutic effects of proton pump inhibitors are assumed to depend on CYP2C19 genotype status.
T2 402-670 OBJECTIVE denotes We investigated whether CYP2C19 genotype status was related to eradication rates of H pylori by triple proton pump inhibitor-clarithromycin-amoxicillin (INN, amoxicilline) therapy and attempted to establish a strategy for treatment after failure to eradicate H pylori.
T3 680-1213 METHODS denotes A total of 261 patients infected with H pylori completed initial treatment with 20 mg of omeprazole or 30 mg of lansoprazole twice a day, 200 mg of clarithromycin three times a day, and 500 mg of amoxicillin three times a day for 1 week. CYP2C19 genotypes of patients were determined with polymerase chain reaction-restriction fragment length polymorphism analysis. Patients without eradication after initial treatment were retreated with 30 mg of lansoprazole four times daily and 500 mg of amoxicillin four times daily for 2 weeks.
T4 1223-1909 RESULTS denotes Eradication rates for H pylori were 72.7% (95% confidence interval, 64.4%-81.8%), 92.1% (confidence interval, 86.4%-97.3%), and 97.8% (confidence interval, 88.5%-99.9%) in the homozygous extensive, heterozygous extensive, and poor metabolizer groups, respectively. Thirty-four of 35 patients without eradication had an extensive metabolizer genotype of CYP2C19. Nineteen of those patients were infected with clarithromycin-resistant strains of H pylori. However, there were no amoxicillin-resistant strains of H pylori. Re-treatment of H pylori infection with dual high-dose lansoprazole-amoxicillin therapy succeeded in 30 of 31 patients with extensive metabolizer genotype of CYP2C19.
T5 1922-2257 CONCLUSIONS denotes The majority of patients without initial eradication of H pylori had an extensive metabolizer CYP2C19 genotype but were successfully re-treated with high doses of lansoprazole and an antibiotic to which H pylori was sensitive, such as amoxicillin, even when the patients were infected with clarithromycin-resistant strains of H pylori.